While many companies have recently incorporated switching studies, I'm not aware of any multiple back and forth studies. Maybe everyone has to start from ground zero.
These patients will be hard to find and I'm not sure how long these studies will take. This should thin the number of entrants.
Market Data 
Markets 
AI
